These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

335 related articles for article (PubMed ID: 31290996)

  • 1. A phase 1 and randomized, placebo-controlled phase 2 trial of bevacizumab plus dasatinib in patients with recurrent glioblastoma: Alliance/North Central Cancer Treatment Group N0872.
    Galanis E; Anderson SK; Twohy EL; Carrero XW; Dixon JG; Tran DD; Jeyapalan SA; Anderson DM; Kaufmann TJ; Feathers RW; Giannini C; Buckner JC; Anastasiadis PZ; Schiff D
    Cancer; 2019 Nov; 125(21):3790-3800. PubMed ID: 31290996
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Randomized phase 2 study of carboplatin and bevacizumab in recurrent glioblastoma.
    Field KM; Simes J; Nowak AK; Cher L; Wheeler H; Hovey EJ; Brown CS; Barnes EH; Sawkins K; Livingstone A; Freilich R; Phal PM; Fitt G; ; Rosenthal MA
    Neuro Oncol; 2015 Nov; 17(11):1504-13. PubMed ID: 26130744
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase II study of panobinostat in combination with bevacizumab for recurrent glioblastoma and anaplastic glioma.
    Lee EQ; Reardon DA; Schiff D; Drappatz J; Muzikansky A; Grimm SA; Norden AD; Nayak L; Beroukhim R; Rinne ML; Chi AS; Batchelor TT; Hempfling K; McCluskey C; Smith KH; Gaffey SC; Wrigley B; Ligon KL; Raizer JJ; Wen PY
    Neuro Oncol; 2015 Jun; 17(6):862-7. PubMed ID: 25572329
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase II Study of Bevacizumab and Vorinostat for Patients with Recurrent World Health Organization Grade 4 Malignant Glioma.
    Ghiaseddin A; Reardon D; Massey W; Mannerino A; Lipp ES; Herndon JE; McSherry F; Desjardins A; Randazzo D; Friedman HS; Peters KB
    Oncologist; 2018 Feb; 23(2):157-e21. PubMed ID: 29133513
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase 2 trial of dasatinib in target-selected patients with recurrent glioblastoma (RTOG 0627).
    Lassman AB; Pugh SL; Gilbert MR; Aldape KD; Geinoz S; Beumer JH; Christner SM; Komaki R; DeAngelis LM; Gaur R; Youssef E; Wagner H; Won M; Mehta MP
    Neuro Oncol; 2015 Jul; 17(7):992-8. PubMed ID: 25758746
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Retrospective study of dasatinib for recurrent glioblastoma after bevacizumab failure.
    Lu-Emerson C; Norden AD; Drappatz J; Quant EC; Beroukhim R; Ciampa AS; Doherty LM; Lafrankie DC; Ruland S; Wen PY
    J Neurooncol; 2011 Aug; 104(1):287-91. PubMed ID: 21153679
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma.
    Friedman HS; Prados MD; Wen PY; Mikkelsen T; Schiff D; Abrey LE; Yung WK; Paleologos N; Nicholas MK; Jensen R; Vredenburgh J; Huang J; Zheng M; Cloughesy T
    J Clin Oncol; 2009 Oct; 27(28):4733-40. PubMed ID: 19720927
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bevacizumab and temozolomide versus temozolomide alone as neoadjuvant treatment in unresected glioblastoma: the GENOM 009 randomized phase II trial.
    Balana C; De Las Penas R; Sepúlveda JM; Gil-Gil MJ; Luque R; Gallego O; Carrato C; Sanz C; Reynes G; Herrero A; Ramirez JL; Pérez-Segura P; Berrocal A; Vieitez JM; Garcia A; Vazquez-Estevez S; Peralta S; Fernandez I; Henriquez I; Martinez-Garcia M; De la Cruz JJ; Capellades J; Giner P; Villà S
    J Neurooncol; 2016 May; 127(3):569-79. PubMed ID: 26847813
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase II study of carboplatin, irinotecan, and bevacizumab for bevacizumab naïve, recurrent glioblastoma.
    Reardon DA; Desjardins A; Peters KB; Gururangan S; Sampson JH; McLendon RE; Herndon JE; Bulusu A; Threatt S; Friedman AH; Vredenburgh JJ; Friedman HS
    J Neurooncol; 2012 Mar; 107(1):155-64. PubMed ID: 21986722
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Advantages and Disadvantages of Combined Chemotherapy with Carmustine Wafer and Bevacizumab in Patients with Newly Diagnosed Glioblastoma: A Single-Institutional Experience.
    Akiyama Y; Kimura Y; Enatsu R; Mikami T; Wanibuchi M; Mikuni N
    World Neurosurg; 2018 May; 113():e508-e514. PubMed ID: 29476996
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bevacizumab and temozolomide in patients with first recurrence of WHO grade II and III glioma, without 1p/19q co-deletion (TAVAREC): a randomised controlled phase 2 EORTC trial.
    van den Bent MJ; Klein M; Smits M; Reijneveld JC; French PJ; Clement P; de Vos FYF; Wick A; Mulholland PJ; Taphoorn MJB; Lewis J; Weller M; Chinot OL; Kros JM; de Heer I; Verschuere T; Coens C; Golfinopoulos V; Gorlia T; Idbaih A
    Lancet Oncol; 2018 Sep; 19(9):1170-1179. PubMed ID: 30115593
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Phase II trial of tandutinib (MLN 518) in combination with bevacizumab for patients with recurrent glioblastoma.
    Odia Y; Sul J; Shih JH; Kreisl TN; Butman JA; Iwamoto FM; Fine HA
    CNS Oncol; 2016; 5(2):59-67. PubMed ID: 26860632
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A meta-analysis of bevacizumab alone and in combination with irinotecan in the treatment of patients with recurrent glioblastoma multiforme.
    Zhang G; Huang S; Wang Z
    J Clin Neurosci; 2012 Dec; 19(12):1636-40. PubMed ID: 23047061
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase II study of ERC1671 plus bevacizumab versus bevacizumab plus placebo in recurrent glioblastoma: interim results and correlations with CD4
    Bota DA; Chung J; Dandekar M; Carrillo JA; Kong XT; Fu BD; Hsu FP; Schönthal AH; Hofman FM; Chen TC; Zidovetzki R; Pretto C; Strik A; Schijns VE; Stathopoulos A
    CNS Oncol; 2018 Jul; 7(3):CNS22. PubMed ID: 30157683
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The added value of bevacizumab concomitantly administered with carboplatin versus carboplatin alone in patients with recurrent glioblastomas.
    Kaloshi G; Diamandi P; Cakani B; Brace G; Rroji A; Petrela M
    Tumori; 2015; 101(1):41-5. PubMed ID: 25702676
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase 1 dose-escalation study of the antiplacental growth factor monoclonal antibody RO5323441 combined with bevacizumab in patients with recurrent glioblastoma.
    Lassen U; Chinot OL; McBain C; Mau-Sørensen M; Larsen VA; Barrie M; Roth P; Krieter O; Wang K; Habben K; Tessier J; Lahr A; Weller M
    Neuro Oncol; 2015 Jul; 17(7):1007-15. PubMed ID: 25665807
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase II study of bevacizumab in combination with sorafenib in recurrent glioblastoma (N0776): a north central cancer treatment group trial.
    Galanis E; Anderson SK; Lafky JM; Uhm JH; Giannini C; Kumar SK; Kimlinger TK; Northfelt DW; Flynn PJ; Jaeckle KA; Kaufmann TJ; Buckner JC
    Clin Cancer Res; 2013 Sep; 19(17):4816-23. PubMed ID: 23833308
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Single-agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial.
    Taal W; Oosterkamp HM; Walenkamp AM; Dubbink HJ; Beerepoot LV; Hanse MC; Buter J; Honkoop AH; Boerman D; de Vos FY; Dinjens WN; Enting RH; Taphoorn MJ; van den Berkmortel FW; Jansen RL; Brandsma D; Bromberg JE; van Heuvel I; Vernhout RM; van der Holt B; van den Bent MJ
    Lancet Oncol; 2014 Aug; 15(9):943-53. PubMed ID: 25035291
    [TBL] [Abstract][Full Text] [Related]  

  • 19. AVAREG: a phase II, randomized, noncomparative study of fotemustine or bevacizumab for patients with recurrent glioblastoma.
    Brandes AA; Finocchiaro G; Zagonel V; Reni M; Caserta C; Fabi A; Clavarezza M; Maiello E; Eoli M; Lombardi G; Monteforte M; Proietti E; Agati R; Eusebi V; Franceschi E
    Neuro Oncol; 2016 Sep; 18(9):1304-12. PubMed ID: 26951379
    [TBL] [Abstract][Full Text] [Related]  

  • 20. NRG/RTOG 1122: A phase 2, double-blinded, placebo-controlled study of bevacizumab with and without trebananib in patients with recurrent glioblastoma or gliosarcoma.
    Lee EQ; Zhang P; Wen PY; Gerstner ER; Reardon DA; Aldape KD; deGroot JF; Pan E; Raizer JJ; Kim LJ; Chmura SJ; Robins HI; Connelly JM; Battiste JD; Villano JL; Wagle N; Merrell RT; Wendland MM; Mehta MP
    Cancer; 2020 Jun; 126(12):2821-2828. PubMed ID: 32154928
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.